CME Presentations

DMD

Presentations

Speakers

  • John F. Brandsema, MD

    John F. Brandsema, MD

    John F. Brandsema, MD

    Child Neurologist, Neuromuscular Section Head

    John Brandsema, MD, is a child neurologist and the Neuromuscular Section Head at the Children’s Hospital of Philadelphia. He has broad clinical and research interests in neuromuscular diseases, with a particular focus in clinical trials of novel therapies for childhood neuromuscular disorders and is enthusiastic about the promise that medical and scientific advances hold for people with these conditions. Dr. Brandsema is involved with clinical trials of novel therapeutics for neuromuscular disorders. His philosophy of care centers around developing strong partnerships with families and empowering parents to understand their child’s medical condition. Outside of the hospital, he is a classically-trained singer and musician and a budding Philadelphia sports fan.

    Session Appearances

    Duchenne Muscular Dystrophy: Recognizing Its Earliest Signs in Infancy and Care Transition into Adulthood

    Practical Considerations with Gene-Transfer Therapy for Patients with DMD

  • Emma Ciafaloni, MD, FAAN

    Emma Ciafaloni, MD, FAAN

    Emma Ciafaloni, MD, FAAN

    Professor in Experimental Therapeutics of Neurologic Disease-Professor of Neurology, Pediatrics and Obstetrics and Gynecology, Director of the Pediatric Neuromuscular Medicine Program

    Emma Ciafaloni, MD, FAAN, is the Robert C. and Rosalyne H. Griggs Professor in Experimental Therapeutics of Neurologic Disease-Professor of Neurology, Pediatrics and Obstetrics and Gynecology at the University of Rochester (Rochester). She is Director of the Pediatric Neuromuscular Medicine Program at Rochester and leads many clinical programs there, including the SMA and Duchenne multidisciplinary clinics. Dr. Ciafaloni has devoted her career to the diagnosis and treatment of adult and pediatric patients with neuromuscular diseases, particularly patients with SMA and myasthenia gravis. Her research interests have focused on experimental therapeutics in neuromuscular disease and she has been involved in clinical trials in pediatric and adult neuromuscular diseases for almost 3 decades.

    Session Appearances

    Duchenne Muscular Dystrophy: Recognizing Its Earliest Signs in Infancy and Care Transition into Adulthood

CME Information

   
PIM LogoPQH Logo

Duchenne Muscular Dystrophy: Recognizing Its Earliest Signs in Infancy and Care Transition into Adulthood

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with Parent Project Muscular Dystrophy (PPMD) and the National Organization for Rare Disorders (NORD).

ACKNOWLEDGEMENT

This activity is supported by educational grants from PTC Therapeutics, Inc. and Sarepta Therapeutics, Inc.

TUITION

Complimentary
JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

DATE OF LIVE ACTIVITY

Tuesday, March 28, 2023 from 3:00 – 4:00pm ET

LIVE CREDIT DESIGNATION STATEMENTS

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF ENDURING MATERIAL RELEASE/EXPIRATION

The enduring material will be available from March 28, 2023 to March 28, 2024.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Summarize the early signs of muscle injury that often precede development of visible symptoms in DMD
  • Define how genetic testing can influence treatment decisions
  • Explain how early treatment with DMTs can alter the natural history of DMD
  • Examine functional and non-functional outcomes and how they influence the definition of treatment success
  • Identify components of multidisciplinary care for patients with DMD, including optimizing mood, bone health, and plans to transition from pediatric to adult care

    • TARGET AUDIENCE

    The intended audience for this activity are neurologists, neuromuscular specialists, pediatric neurologists, genetic counselors, and pediatricians.

    ESTIMATED TIME TO COMPLETE

    This activity should take approximately 1 hour to complete.

    METHOD OF PARTICIPATION

    There are no fees to participate in this activity. To participate in the activity, go to www.NeuroSeriesLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

    HARDWARE/SOFTWARE REQUIREMENTS

    Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

    DISCLOSURE OF CONFLICTS OF INTEREST

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


    Name of Faculty or Presenter Reported Financial Relationship
    John Brandsema, MD
    Child Neurologist
    Neuromuscular Section Head
    Children’s Hospital of Philadelphia     		Grant/Research Support: Alexion, Astellas, AveXis/Novartis, Biogen, CSL Behring, Fibrogen, Genentech, Pfizer, PTC Therapeutics, Sarepta
    Consultant/Advisory Board: AveXis/Novartis, Biogen, Genentech, Janssen, Pfizer, PTC Therapeutics, Sarepta
    Emma Ciafaloni, MD
    Professor of Neurology and Pediatrics
    University of Rochester     		Grant/Research Support: Sarepta
    Consultant/Advisory Board: Alexion, Sarepta

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Name of Planner Reported Financial Relationship
    Carole Drexel
    Medical Director
    PlatformQ Health Education, LLC     		None
    Vandana Gupta
    Medical Director
    PlatformQ Health Education, LLC     		None

    The PIM planners and managers have nothing to disclose.

    The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

    DISCLOSURE OF UNAPPROVED/OFF LABEL USE:

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER:

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    CONTACT INFORMATION

    Accreditation Support:
    Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

    Technical Support:
    For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive.com at 877-394-1306 or at Support@NeuroSeriesLive.com.